Global Peptide Antibiotics Market Research 2024, Forecast To 2033
22 Feb, 2024
The peptide antibiotics market has grown rapidly, increasing from $4.79 billion in 2023 to $5.31 billion in 2024, with an 11.0% CAGR. This is linked to antibiotic resistance and advancements in peptide synthesis. Forecasts suggest continued growth to $7.78 billion in 2028, driven by novel antibiotics development. Key trends include exploration of natural sources and AI integration.
Global Peptide Antibiotics Market Key Driver
The peptide antibiotics market is expected to grow with the increasing prevalence of various infectious diseases. Factors such as rapid urbanization and climate change contribute to the rise in infectious diseases. With cases of notifiable infectious diseases in Australia growing from 2.89 million in 2020 to 7.02 million in 2021, the demand for peptide antibiotics is expected to increase.
Get A Free Sample Of The Global Peptide Antibiotics Market ReportGlobal Peptide Antibiotics Market Segments
The peptide antibiotics market covered in this report is segmented –
1)By Type: Ribosomal Synthesized Peptide Antibiotics, Non-rRibosomal Synthesized Peptide Antibiotics
2)By Drugs: Daptomycin, Dalbavancin, Telavancin, Other Drugs
3)By Disease Outlook: Skin Infection, HABP/VABP, Blood Stream Infection, Other Diseases
4)By Distribution Channel: Hospitals, Homecare, Specialty Clinics, Other Distribution Channels
By Geography: The regions covered in the template market report are Asia-Pacific, Western Europe, Eastern Europe,North America, South America, Middle East, and Africa. Among these regions.
North America was the largest region in the peptide antibiotics market in 2023. The regions covered in the peptide antibiotics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Major Peptide Antibiotics Industry Players
Eli Lilly and Company; GlaxoSmithKline plc; Novartis AG; Pfizer Inc.; Theravance Biopharma Inc.; Merck & Co. Inc.; AbbVie Inc.; Sandoz International GmbH; Xellia APS; AuroMedics Pharma LLC; EnBiotix Inc.; Johnson & Johnson Inc.; AstraZeneca PLC; Bayer AG; Bristol-Myers Squibb Company; Lupin Pharmaceuticals Inc.; Sun Pharmaceutical Industries Ltd.; Teva Pharmaceutical Industries Ltd.; Torrent Pharmaceuticals Ltd.; Wockhardt Ltd.; Zydus Lifesciences Limited; Alkem Laboratories Limited; AdvaCare Pharma; Allecra Therapeutics GmbH; AmpliPhi Biosciences Corporation; Antabio; Arsanis Inc.; Basilea Pharmaceutica Ltd.; BioVersys AG; Curis Inc.
Get The Full Global Peptide Antibiotics Market Report
Peptide Antibiotics Market Overview
Peptide antibiotics refer to antibiotics made up of peptides the physical rupture of cell membranes underpins the antibacterial activity. The peptide antibiotics are used to permeate bacterial membranes, collect within bacteria, and then interfere with bacterial functioning.
Peptide Antibiotics Global Market Report 2023 provides data on the global peptide antibiotics market such as market size, growth forecasts, segments and geographies, competitive landscape including leading competitors’ revenues, profiles and market shares. The peptide antibiotics market report identifies opportunities and strategies based on market trends and leading competitors’ approaches.